Placebo News and Research

RSS

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Isis Pharmaceuticals, Inc. announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

16 Jul 2014

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals, Inc. today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura).

16 Jul 2014

Hydroxychloroquine treatment not effective for primary Sjögren syndrome

Among patients with the systemic autoimmune disease primary Sjögren syndrome, use of hydroxychloroquine, the most frequently prescribed treatment for the disorder, did not improve symptoms during 24 weeks of treatment compared with placebo, according to a study in the July 16 issue of JAMA.

16 Jul 2014

‘No convincing evidence’ for zinc supplements to prevent otitis media

There is no convincing evidence that zinc supplements reduce the risk of otitis media in children or adults, say the authors of an updated Cochrane review.

15 Jul 2014

B vitamins do not prevent Alzheimer's disease

Taking B vitamins doesn't slow mental decline as we age, nor is it likely to prevent Alzheimer's disease, conclude Oxford University researchers who have assembled all the best clinical trial data involving 22,000 people to offer a final answer on this debate.

15 Jul 2014

Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Firstly, paracetamol has been the first-line recommended treatment for osteoarthritis pain for very many years and, secondly, it is readily available over the counter and can be bought in relatively large quantities.

15 Jul 2014

BAI and Novartis determine whether investigational drugs can prevent symptoms of Alzheimer's

Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs-an active immunotherapy and an oral medication-can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.

15 Jul 2014

CRAG urges researchers to balance goal of shortening treatment for MDR-TB with patient safety

In a viewpoint published this week in The Lancet, the Community Research Advisors Group argue that research into bedaquiline – a new drug, fast tracked for multidrug-resistant tuberculosis (MDR-TB) – should proceed cautiously in people with drug-sensitive tuberculosis.

14 Jul 2014

CYD-TDV vaccine shows moderate protection against dengue in Asian children

The first dengue vaccine candidate (CYD-TDV) to reach phase 3 clinical testing has shown moderate protection (56%) against the disease in Asian children, according to new research published in The Lancet.

14 Jul 2014

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program.

10 Jul 2014

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon® issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan.

10 Jul 2014

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection.

10 Jul 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.

10 Jul 2014

Placebo News and Research

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Hydroxychloroquine treatment not effective for primary Sjögren syndrome

‘No convincing evidence’ for zinc supplements to prevent otitis media

B vitamins do not prevent Alzheimer's disease

Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

BAI and Novartis determine whether investigational drugs can prevent symptoms of Alzheimer's

CRAG urges researchers to balance goal of shortening treatment for MDR-TB with patient safety

CYD-TDV vaccine shows moderate protection against dengue in Asian children

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Pain control in osteoarthritis patients

Combining NRT with varenicline improves smoking abstinence

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Study analyzes effects of antidepressant drugs on well-being in children and adolescents

Study shows how psychedelic drug alters brain activity to produce unusual psychological effects

Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

New research examines brain effects of the psychedelic chemical in magic mushrooms

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News